Table 2.

Nuclease detection methods

Nuclease	Detection method	Reference
FEN1	Cancer Profiling Array I	[24]
	IHC	[24, 25]
	semiquantitative reverse transcription-PCR	[25]
APE1	IHC	[26–29, 33, 39]
	radioactivity-based or fluorescence- based nuclease activity assay	[20]
	ELISA	[30, 34, 36]
	liquid chromatography and tandem mass spectrometry with isotope dilution	[31]
	genotyping assays and in silico prediction	[32]
	RT-qPCR	[35]
	qPCR	[37]
	PCR	[38]
	RFLP	[38]
	whole genome gene expression of melanoma tumors, using Illumina DASL approach	[40]
XPF/XPG	IHC	[21, 42, 44]
	RT-qPCR	[45]
MRN Complex	IHC	[47–50]
	PCR	[48, 49, 51]
TREX2	knock out mouse model, IHC, ssDNA and dsDNA degradation assays	[52]
SND1	IHC	[53, 56]
	chicken chorioallantoic membrane assay, human umbilical vein endothelial cell differentiation assay	[54]
	RT-qPCR	[57]
DNaseI	phenotyping conducted on urine samples from participants, using electrophoresis in thin polyacrylamide gel followed by immunoblotting with an antihuman DNaseI antibody	[58, 59]
RNaseL	gene sequencing, 5′ nuclease TaqMan® allelic discrimination assay, genotyping using PCR and WAVE DHPLC	[60, 61]
	enzymatic assay using rRNA as a substrate	[62]
	analysis of tumor DNA and genotyping of somatic tissues of patients	[63]
RNaseI	WB, ELISA, and immunoprecipitation	[64, 65]
Serum RNase activity	serum RNase enzymatic activity was assayed using two substrates: t-RNA (T) from E. coli MRE 600 and the synthetic polycytidylic acid (poly-C). Elevated serum ribonuclease activity (SRA) was expressed in terms of the amount of bovine serum RNaseA from bovine pancreas in ngeq/ml that yields the same extinction Coeff. at the 260 nm wavelength.	[66]